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Conclusion: This study underlines the lack of awareness towards cardio-
vascular risk factors in the management of dyslipidemia, particularly while
considering the implementation time of a lipid lowering therapy.
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Purpose: Current guidelines recommend lowering LDL-cholesterol below
2.6 mmol/L in patients with established cardiovascular disease. The potential ben-
efit of an additional decrease in LDL-cholesterol has been suggested for coronary
heart disease patients with diabetes or dysmetabolic profile, as they are at high risk
of recurrence. The aim of this analysis was to estimate the proportion of patients
with poor metabolic profile among those with established coronary heart disease.
Methods: A sample of French male patients with a history of acute coro-
nary syndrome was recruited from 2001 to 2004. Those with recent (in the
past two months) acute coronary syndrome were excluded.
Results: The sample comprised 824 men. Mean age was 60.3 years (stan-
dard deviation: 7.9), 22% of patients were still current smokers and 65% had
high blood pressure (≥ 140/90 or 130/80 mmHg if diabetes). Diabetes was
encountered in 32% of patients (20%, 36% and 38% from the 10-year age
group 45-54 to 65-74 years, respectively, p<0.0001), low HDL-cholesterol (<
1 mmol/L) was observed in 42% (48%, 43%, 36%, p=0.021), high triglycer-
ides (≥ 1.7 mmol/L) in 48% (58%, 49%, 38%, p<0.0001), and high non-HDL
cholesterol (≥ 3.4 mmol/L) in 74% of patients (84%, 77%, 64%, p<0.0001).
The combination of high non-HDL cholesterol and high triglycerides which
reflects the atherogenic potential associated with remnant lipoproteins was
encountered in 42% of patients (54%, 42%, 31%, p<0.0001) and 24% (32%,
24%, 17%, p<0.001) had a dysmetabolic profile (low HDL-cholesterol plus
high non HDL-cholesterol and elevated triglycerides). Overall, 48% of patients
(47%, 50%, 48%, p=0.706) presented either with diabetes or dysmetabolic
profile, and thus should be considered at very high risk.
Conclusions: These data suggest that almost one half of patients with estab-
lished coronary heart disease could be at very high risk, and may thus require a
more intensive strategy to control lipids and to reduce global cardiovascular risk.
296
Trends in plasma lipids, lipoproteins and dyslipidemias in French
adults, 1996-2007
Jean Ferrières (1), Vanina Bongard (2), Jean Dallongeville (3), Dominique
Arveiler (4), Dominique Cottel (5), Bernadette Haas (6), Aline Wagner
(6), Philippe Amouyel (3), Jean-Bernard Ruidavets (2)
(1) CHU Rangueil, Service de Cardiologie B, Toulouse Cedex 9, France –
(2) CHU, University School of Medicine, Epidemiology, INSERM U558,
Toulouse, France – (3) INSERM U744, Institut Pasteur, Lille, France – (4)
Strasbourg University School of Medicine, Epidemiology and Public
Health, Strasbourg, France – (5) INSERM U744, Unité d’Epidémiologie et
de Santé Publique, Lille Cedex, France – (6) Faculté de Médecine, Labo-
ratoire d’Epidémiologie et de Santé Publique, Strasbourg Cedex, France
Background: The management of dyslipidemias remains a priority of pre-
ventive cardiology. The aim of this work was to assess lipids, lipoproteins and
dyslipidemias trends between 1996 and 2007 in France.
Methods: Two representative surveys of the general population were car-
ried out in Northern, in North-Eastern and in Southwestern areas of France in
1996-97 (n=3508) and in 2006-07 (n=3597). Men and women aged 35 to 64
years were included. The investigators recorded all the cardiovascular risk fac-
tors and a blood sample was drawn. Data have been rectified with the respec-
tive original populations to study a 10-year trend in the measured parameters.
Results: From 1996 to 2007, a significant 5.7% decrease in LDL-choles-
terol (C) levels was observed in adults aged 35-64 years (p<0.001). During
this same period a significant 7.8% increase in triglycerides was observed
(p<0.001). LDL-C variation was more striking in subjects treated with a lipid-
lowering drug, with a 17.6% reduction (p<0.001). Lipid-lowering drug preva-
lence increased significantly from 10.4% to 12.5% between the two periods
(p=0.004). In 1996-97, 33.7% of the dyslipidemic subjects were treated with
statins and 71.8% in 2006-07. In 2006-07, atorvastatin was the most com-
monly prescribed statin (35.8% of all statins) whereas the most common
fibrate was fenofibrate (87.2% of all fibrates). A decrease in most of dyslipi-
demias (LDL-C >4.1 mmol/L or triglycerides ≥2.3 mmol/L or HDL-C <1.05
mmol/L in men or <1.3 mmol/L in women) has also been observed at a 10-
year interval. On the other hand, we observed a significant increase in the
combination of hypertriglyceridemia with high LDL-C.
Conclusion: This study shows a favorable trend in LDL-C and dyslipi-
demias in France. The significant decrease in LDL-C observed among all the
subjects and more particularly among subjects treated with lipid-lowering drugs
should be incentive for physicians to support the management of all adults.
297
Antimicrobial prophylaxis before defibrillator and pace-maker
implantation : a retrospective study
Frederique Sauer (1), Laurence Jesel (1), Nicolas Meyer (2), Patrick Ohl-
mann (1), Yves Hansmann (3), Michel Chauvin (1)
(1) Hopitaux Universitaires de Strasbourg, Cardiologie, Strasbourg,
France – (2) Hopitaux Universitaires de Strasbourg, Institut de Statisti-
ques médicales et d’épidémiologie, Strasbourg, France – (3) Hopitaux
Universitaires de Strasbourg, Maladies infectieuses et tropicales, Stras-
bourg, France
Background: the implantation of pace maker or defibrillator expose to the
risk of infection of these devices. The use of antimicrobial prophylaxis before
implantation is not clearly recommended, because there are only few studies
that establish its benefit.
Patients and methods: we conducted a retrospective case control study
between 2004 and 2007, to determine the risk factor associated with infection,
especially if the administration of an antimicrobial prophylaxis is associated
with decrease of devices infection. Inclusion criteria were following: presence
of wound inflammation, or device externalisation, and Klug’s modified Dukes
criteria for endocarditis. All micro-organisms results from deep wound sample
or blood culture.
Results: 979 patients had a non valvular cardiac device during the study
period. 34 of them developed infectious complication (incidence 3.5 %) : 19
local infections, and 15 endocarditis. 70 patients constituted the age and sex
matched control population. Staphylococcus was isolated in 88 % of the cases.
27 % of them were S. aureus. 53 % of Staphylococcus were resistant to meti-
cillin. The risk factors associated with infection were following : number of
surgical interventions related to the cardiac devices (p < 0.001), early wound
inflammation or hematoma (p < 0.001), INR or partial thromboplastin time
ratio > 1.5 the day of implantation, fever before implantation (p< 0.001), more
infections after defibrillator implantation vs pace maker (p = 0.03) and
absence of antibioprohylaxis (p = 0.03). Antibioprophyxis were in majority of
case intra venous cephalosporin (16/17).
Conclusion: antibioprophylaxis and surveillance of anticoagulation could
be helpful to prevent infection after cardiac devices implantation; prospective
studies could be interesting to confirm these results. 
Table.  Risk factors for cardiac device infection
Risk factors for infection p
Number of surgical operation related to cardiac device p<0.001
Early wound inflammation or hematoma p<0.001
INR or partial thromboplastin time ratio > 1.5 p<0.015
Fever before implantation p<0.001
Defibrillator implantation versus pacemaker p=0.03
Absence of antibioprophylaxis p<0.03
